TW205035B - - Google Patents
Download PDFInfo
- Publication number
- TW205035B TW205035B TW080109719A TW80109719A TW205035B TW 205035 B TW205035 B TW 205035B TW 080109719 A TW080109719 A TW 080109719A TW 80109719 A TW80109719 A TW 80109719A TW 205035 B TW205035 B TW 205035B
- Authority
- TW
- Taiwan
- Prior art keywords
- compound
- methyl
- solution
- water
- patent application
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 claims description 47
- 239000000243 solution Substances 0.000 claims description 34
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 31
- 206010019233 Headaches Diseases 0.000 claims description 17
- 231100000869 headache Toxicity 0.000 claims description 17
- 238000000034 method Methods 0.000 claims description 14
- 239000000203 mixture Substances 0.000 claims description 13
- 239000004480 active ingredient Substances 0.000 claims description 10
- 239000007864 aqueous solution Substances 0.000 claims description 10
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 10
- 239000002904 solvent Substances 0.000 claims description 9
- 150000003839 salts Chemical class 0.000 claims description 8
- -1 amine salt Chemical class 0.000 claims description 7
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 claims description 4
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 235000015090 marinades Nutrition 0.000 claims 1
- 239000007788 liquid Substances 0.000 description 15
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 12
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 12
- 238000002347 injection Methods 0.000 description 10
- 239000007924 injection Substances 0.000 description 10
- 239000003814 drug Substances 0.000 description 9
- 238000011049 filling Methods 0.000 description 9
- 238000009472 formulation Methods 0.000 description 9
- 230000001954 sterilising effect Effects 0.000 description 7
- 238000004659 sterilization and disinfection Methods 0.000 description 7
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 239000011734 sodium Substances 0.000 description 5
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 4
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 4
- 239000003513 alkali Substances 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 229910052708 sodium Inorganic materials 0.000 description 4
- KDYFGRWQOYBRFD-UHFFFAOYSA-N succinic acid Chemical compound OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 4
- 239000002253 acid Substances 0.000 description 3
- 230000002421 anti-septic effect Effects 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 238000000855 fermentation Methods 0.000 description 3
- 230000004151 fermentation Effects 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 150000003385 sodium Chemical class 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 2
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 description 2
- DGMOQCHIPOPXEK-UHFFFAOYSA-N Spermic acid 2 Chemical compound OC(=O)CCNCCCCNCCC(O)=O DGMOQCHIPOPXEK-UHFFFAOYSA-N 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 150000001412 amines Chemical class 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 239000012736 aqueous medium Substances 0.000 description 2
- 229940072107 ascorbate Drugs 0.000 description 2
- 235000010323 ascorbic acid Nutrition 0.000 description 2
- 239000011668 ascorbic acid Substances 0.000 description 2
- 239000002585 base Substances 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- KCXMKQUNVWSEMD-UHFFFAOYSA-N benzyl chloride Chemical compound ClCC1=CC=CC=C1 KCXMKQUNVWSEMD-UHFFFAOYSA-N 0.000 description 2
- 229940073608 benzyl chloride Drugs 0.000 description 2
- 238000004090 dissolution Methods 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- LNTHITQWFMADLM-UHFFFAOYSA-N gallic acid Chemical compound OC(=O)C1=CC(O)=C(O)C(O)=C1 LNTHITQWFMADLM-UHFFFAOYSA-N 0.000 description 2
- 230000008570 general process Effects 0.000 description 2
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- UHOVQNZJYSORNB-UHFFFAOYSA-N monobenzene Natural products C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 2
- 239000004033 plastic Substances 0.000 description 2
- 229920003023 plastic Polymers 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- ATHGHQPFGPMSJY-UHFFFAOYSA-N spermidine Chemical compound NCCCCNCCCN ATHGHQPFGPMSJY-UHFFFAOYSA-N 0.000 description 2
- 239000001384 succinic acid Substances 0.000 description 2
- BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 description 2
- 239000008215 water for injection Substances 0.000 description 2
- STGNLGBPLOVYMA-MAZDBSFSSA-N (E)-but-2-enedioic acid Chemical compound OC(=O)\C=C\C(O)=O.OC(=O)\C=C\C(O)=O STGNLGBPLOVYMA-MAZDBSFSSA-N 0.000 description 1
- DSSYKIVIOFKYAU-XCBNKYQSSA-N (R)-camphor Chemical compound C1C[C@@]2(C)C(=O)C[C@@H]1C2(C)C DSSYKIVIOFKYAU-XCBNKYQSSA-N 0.000 description 1
- LVGUZGTVOIAKKC-UHFFFAOYSA-N 1,1,1,2-tetrafluoroethane Chemical compound FCC(F)(F)F LVGUZGTVOIAKKC-UHFFFAOYSA-N 0.000 description 1
- DDMOUSALMHHKOS-UHFFFAOYSA-N 1,2-dichloro-1,1,2,2-tetrafluoroethane Chemical compound FC(F)(Cl)C(F)(F)Cl DDMOUSALMHHKOS-UHFFFAOYSA-N 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 241000723346 Cinnamomum camphora Species 0.000 description 1
- 208000006561 Cluster Headache Diseases 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 1
- 239000005977 Ethylene Substances 0.000 description 1
- 244000166124 Eucalyptus globulus Species 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 235000006679 Mentha X verticillata Nutrition 0.000 description 1
- 235000002899 Mentha suaveolens Nutrition 0.000 description 1
- 235000001636 Mentha x rotundifolia Nutrition 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- 241000237852 Mollusca Species 0.000 description 1
- 240000002853 Nelumbo nucifera Species 0.000 description 1
- 235000006508 Nelumbo nucifera Nutrition 0.000 description 1
- 235000006510 Nelumbo pentapetala Nutrition 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 229920002565 Polyethylene Glycol 400 Polymers 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- 206010043269 Tension headache Diseases 0.000 description 1
- 208000008548 Tension-Type Headache Diseases 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 238000005273 aeration Methods 0.000 description 1
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 1
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 1
- 235000011130 ammonium sulphate Nutrition 0.000 description 1
- JXLHNMVSKXFWAO-UHFFFAOYSA-N azane;7-fluoro-2,1,3-benzoxadiazole-4-sulfonic acid Chemical compound N.OS(=O)(=O)C1=CC=C(F)C2=NON=C12 JXLHNMVSKXFWAO-UHFFFAOYSA-N 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- WGQKYBSKWIADBV-UHFFFAOYSA-O benzylaminium Chemical compound [NH3+]CC1=CC=CC=C1 WGQKYBSKWIADBV-UHFFFAOYSA-O 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 229910052793 cadmium Inorganic materials 0.000 description 1
- BDOSMKKIYDKNTQ-UHFFFAOYSA-N cadmium atom Chemical compound [Cd] BDOSMKKIYDKNTQ-UHFFFAOYSA-N 0.000 description 1
- 229960000846 camphor Drugs 0.000 description 1
- 229930008380 camphor Natural products 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000005660 chlorination reaction Methods 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 208000018912 cluster headache syndrome Diseases 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 229940087091 dichlorotetrafluoroethane Drugs 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 238000004980 dosimetry Methods 0.000 description 1
- 238000005538 encapsulation Methods 0.000 description 1
- 208000016253 exhaustion Diseases 0.000 description 1
- 210000000744 eyelid Anatomy 0.000 description 1
- NBVXSUQYWXRMNV-UHFFFAOYSA-N fluoromethane Chemical compound FC NBVXSUQYWXRMNV-UHFFFAOYSA-N 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 229940074391 gallic acid Drugs 0.000 description 1
- 235000004515 gallic acid Nutrition 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 238000004817 gas chromatography Methods 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- 150000002338 glycosides Chemical class 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 210000003128 head Anatomy 0.000 description 1
- 239000008236 heating water Substances 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 150000002431 hydrogen Chemical class 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 238000005984 hydrogenation reaction Methods 0.000 description 1
- 229910052738 indium Inorganic materials 0.000 description 1
- PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 description 1
- RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 230000001418 larval effect Effects 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 229960003194 meglumine Drugs 0.000 description 1
- OKKJLVBELUTLKV-UHFFFAOYSA-N methanol Substances OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 208000026721 nail disease Diseases 0.000 description 1
- 210000003928 nasal cavity Anatomy 0.000 description 1
- 239000006199 nebulizer Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 125000000286 phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 235000021110 pickles Nutrition 0.000 description 1
- 238000005554 pickling Methods 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 239000003380 propellant Substances 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- 239000012266 salt solution Substances 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 229910052709 silver Inorganic materials 0.000 description 1
- 239000004332 silver Substances 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- KKCBUQHMOMHUOY-UHFFFAOYSA-N sodium oxide Chemical compound [O-2].[Na+].[Na+] KKCBUQHMOMHUOY-UHFFFAOYSA-N 0.000 description 1
- 229910001948 sodium oxide Inorganic materials 0.000 description 1
- 229910052938 sodium sulfate Inorganic materials 0.000 description 1
- 235000011152 sodium sulphate Nutrition 0.000 description 1
- 229940063673 spermidine Drugs 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- TXEYQDLBPFQVAA-UHFFFAOYSA-N tetrafluoromethane Chemical compound FC(F)(F)F TXEYQDLBPFQVAA-UHFFFAOYSA-N 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- CYRMSUTZVYGINF-UHFFFAOYSA-N trichlorofluoromethane Chemical compound FC(Cl)(Cl)Cl CYRMSUTZVYGINF-UHFFFAOYSA-N 0.000 description 1
- 229940029284 trichlorofluoromethane Drugs 0.000 description 1
- 208000019553 vascular disease Diseases 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
- C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
- C07D209/16—Tryptamines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pain & Pain Management (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Indole Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB909026998A GB9026998D0 (en) | 1990-12-12 | 1990-12-12 | Medicaments |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| TW205035B true TW205035B (OSRAM) | 1993-05-01 |
Family
ID=10686904
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TW080109719A TW205035B (OSRAM) | 1990-12-12 | 1991-12-11 | |
| TW081105493A TW300886B (OSRAM) | 1990-12-12 | 1991-12-11 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TW081105493A TW300886B (OSRAM) | 1990-12-12 | 1991-12-11 |
Country Status (36)
| Country | Link |
|---|---|
| US (2) | US5554639A (OSRAM) |
| EP (1) | EP0490689B1 (OSRAM) |
| JP (1) | JP2994037B2 (OSRAM) |
| KR (1) | KR100211479B1 (OSRAM) |
| CN (2) | CN1030890C (OSRAM) |
| AP (1) | AP230A (OSRAM) |
| AT (1) | ATE119881T1 (OSRAM) |
| AU (1) | AU650706B2 (OSRAM) |
| BE (1) | BE1005085A3 (OSRAM) |
| CA (1) | CA2098302C (OSRAM) |
| CH (1) | CH684192A5 (OSRAM) |
| CY (1) | CY2005A (OSRAM) |
| CZ (1) | CZ281931B6 (OSRAM) |
| DE (1) | DE69108200T2 (OSRAM) |
| DK (1) | DK0490689T3 (OSRAM) |
| EG (1) | EG20219A (OSRAM) |
| ES (1) | ES2069836T3 (OSRAM) |
| FR (1) | FR2670487B1 (OSRAM) |
| GB (2) | GB9026998D0 (OSRAM) |
| GR (1) | GR3015430T3 (OSRAM) |
| HK (1) | HK82697A (OSRAM) |
| HU (1) | HU211937A9 (OSRAM) |
| IE (1) | IE62894B1 (OSRAM) |
| IL (1) | IL100330A (OSRAM) |
| IS (1) | IS1706B (OSRAM) |
| IT (1) | IT1252868B (OSRAM) |
| MX (1) | MX9102501A (OSRAM) |
| MY (1) | MY109265A (OSRAM) |
| NL (1) | NL9102071A (OSRAM) |
| NZ (1) | NZ240942A (OSRAM) |
| PT (1) | PT99757B (OSRAM) |
| RU (1) | RU2108328C1 (OSRAM) |
| TW (2) | TW205035B (OSRAM) |
| WO (1) | WO1992010477A1 (OSRAM) |
| YU (1) | YU48926B (OSRAM) |
| ZA (1) | ZA919750B (OSRAM) |
Families Citing this family (63)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0573221B1 (en) * | 1992-06-05 | 1998-04-29 | Merck Sharp & Dohme Ltd. | The sulphate salt of a substituted triazole, pharmaceutical compositions thereof, and their use in therapy |
| FR2749846B1 (fr) * | 1996-06-17 | 1998-09-11 | Pf Medicament | Sel de methanesulfonate d'une arylpiperazine derivee de tryptamine et ses solvates pour usage pharmaceutique |
| US8022095B2 (en) * | 1996-08-16 | 2011-09-20 | Pozen, Inc. | Methods of treating headaches using 5-HT agonists in combination with long-acting NSAIDs |
| US6106837A (en) * | 1997-05-15 | 2000-08-22 | Hirsch; Alan R. | Method of treating headaches, and article of manufacture therefor |
| US6066092A (en) * | 1997-11-06 | 2000-05-23 | Cady; Roger K. | Preemptive prophylaxis of migraine device and method |
| US7189753B1 (en) | 1997-11-06 | 2007-03-13 | Cady Roger K | Preemptive prophylaxis of migraine |
| US6187790B1 (en) | 1999-03-04 | 2001-02-13 | Neal R. Cutler | Use of cilostazol for treatment of sexual dysfunction |
| US6132757A (en) * | 1998-05-01 | 2000-10-17 | Neal R. Cutler | Treatment of sexual dysfunction in certain patient groups |
| US6426084B1 (en) * | 2000-06-19 | 2002-07-30 | Neal R. Cutler | Treatment of sexual dysfunction in certain patient groups |
| GB9926250D0 (en) * | 1999-11-06 | 2000-01-12 | Knoll Ag | Chemical process |
| US6610271B2 (en) * | 2000-05-10 | 2003-08-26 | University Of Kentucky Research Foundation | System and method for intranasal administration of lorazepam |
| US20040115133A1 (en) * | 2000-05-10 | 2004-06-17 | Wermeling Daniel P. | Intranasal opioid compositions |
| US6451813B1 (en) | 2001-01-26 | 2002-09-17 | R. T. Alamo Ventures I, Llc | Treatment of gastroparesis in certain patient groups |
| US6562838B2 (en) | 2001-01-26 | 2003-05-13 | R. T. Alamo Ventures I, L.L.C. | Treatment of cardiovascular disease with quinolinone enantiomers |
| US6458804B1 (en) * | 2001-01-26 | 2002-10-01 | R.T. Alamo Venturesi, Llc | Methods for the treatment of central nervous system disorders in certain patient groups |
| US20040176359A1 (en) * | 2001-02-20 | 2004-09-09 | University Of Kentucky Research Foundation | Intranasal Benzodiazepine compositions |
| US20030096748A1 (en) * | 2001-06-04 | 2003-05-22 | The Regents Of The University Of Michigan | Methods and compositions for the treatment of diseases associated with signal transduction aberrations |
| EP1435945B1 (en) * | 2001-06-05 | 2008-08-13 | Aung-din, Ronald | Topical migraine therapy |
| US8329734B2 (en) | 2009-07-27 | 2012-12-11 | Afgin Pharma Llc | Topical therapy for migraine |
| US7041677B2 (en) * | 2002-03-01 | 2006-05-09 | R.T. Alamo Ventures I, Llc | Use of monochloroflosequinan in the treatment of sexual dysfunction |
| US7208628B2 (en) * | 2002-05-13 | 2007-04-24 | Kansas State University Research Foundation | Compositions and methods for the treatment of hepatitis C virus infection |
| US7074893B2 (en) * | 2002-06-03 | 2006-07-11 | Regents Of The University Of Michigan | Methods and compositions for the treatment of diseases associated with signal transduction aberrations |
| US20040068000A1 (en) * | 2002-10-02 | 2004-04-08 | Mintong Guo | Compression coated tablets |
| SI1575566T1 (sl) * | 2002-12-26 | 2012-08-31 | Pozen Inc | Veäśplastna dozirna oblika vsebujoäśa naproksen in triptane |
| US20080213363A1 (en) * | 2003-01-23 | 2008-09-04 | Singh Nikhilesh N | Methods and compositions for delivering 5-HT3 antagonists across the oral mucosa |
| WO2004076403A1 (en) * | 2003-02-24 | 2004-09-10 | Transform Pharmaceuticals, Inc. | Sumatriptan crystalline forms, pharmaceutical compositions and methods |
| US20070065463A1 (en) * | 2003-06-20 | 2007-03-22 | Ronald Aung-Din | Topical therapy for the treatment of migranes, muscle sprains, muscle spasms, spasticity and related conditions |
| US20050089558A1 (en) * | 2003-10-28 | 2005-04-28 | Alamo Pharmaceuticals, Llc | Compositions and methods for the co-formulation and administration of tramadol and propoxyphene |
| WO2005119607A2 (en) * | 2004-06-03 | 2005-12-15 | Tyfone, Inc. | System and method for securing financial transactions |
| US20060002989A1 (en) * | 2004-06-10 | 2006-01-05 | Ahmed Salah U | Formulations of sumatriptan for absorption across biological membranes, and methods of making and using the same |
| MY147767A (en) | 2004-06-16 | 2013-01-31 | Janssen Pharmaceutica Nv | Novel sulfamate and sulfamide derivatives useful for the treatment of epilepsy and related disorders |
| BRPI0610864A2 (pt) | 2005-05-20 | 2010-08-03 | Janssen Pharmaceutica Nv | processo para preparação de derivados de sulfamida |
| WO2007070504A2 (en) * | 2005-12-13 | 2007-06-21 | Morton Grove Pharmaceuticals, Inc. | Stable and palatable oral liquid sumatriptan compositions |
| US8716231B2 (en) | 2005-12-19 | 2014-05-06 | Janssen Pharmaceutica Nv | Use of benzo-fused heterocycle sulfamide derivatives for the treatment of pain |
| US8691867B2 (en) | 2005-12-19 | 2014-04-08 | Janssen Pharmaceutica Nv | Use of benzo-fused heterocycle sulfamide derivatives for the treatment of substance abuse and addiction |
| AR058389A1 (es) | 2005-12-19 | 2008-01-30 | Janssen Pharmaceutica Nv | Uso de derivados heterociclicos benzo-fusionados de sulfamida para el tratamiento de la obesidad |
| US8937096B2 (en) | 2005-12-19 | 2015-01-20 | Janssen Pharmaceutica Nv | Use of benzo-fused heterocyle sulfamide derivatives for the treatment of mania and bipolar disorder |
| US8497298B2 (en) | 2005-12-19 | 2013-07-30 | Janssen Pharmaceutica Nv | Use of benzo-fused heterocycle sulfamide derivatives for lowering lipids and lowering blood glucose levels |
| US20070191461A1 (en) * | 2006-02-15 | 2007-08-16 | Smith-Swintosky Virginia L | Use of benzo-heteroaryl sulfamide derivatives for the treatment of migraine |
| JP2009537635A (ja) | 2006-05-19 | 2009-10-29 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | 癲癇の処置のための共同−療法 |
| CA2665841C (en) | 2006-10-09 | 2016-04-05 | Charleston Laboratories, Inc. | Pharmaceutical compositions |
| AU2007310949A1 (en) * | 2006-10-19 | 2008-04-24 | Auspex Pharmaceuticals, Inc. | Substituted indoles |
| US20080275030A1 (en) | 2007-01-19 | 2008-11-06 | Sveinbjorn Gizurarson | Methods and Compositions for the Delivery of a Therapeutic Agent |
| GB2448183A (en) * | 2007-04-05 | 2008-10-08 | Optinose As | Nasal powder delivery device |
| ES2620672T3 (es) | 2008-01-09 | 2017-06-29 | Charleston Laboratories, Inc. | Comprimidos de doble capa que comprenden oxicodona y prometazina |
| US20090252791A1 (en) * | 2008-04-02 | 2009-10-08 | Venkata Nookaraju Sreedharala | Pharmaceutical compositions comprising a triptan and a nonsteroidal anti-inflammatory drug |
| NZ590286A (en) | 2008-05-27 | 2011-08-26 | Biota Scient Management | Phosphate and sulphate salts of 6-{ 2-[1-(6-methyl-3-pyrazinyl)-4-piperidinyl]ethoxy} -3-ethoxy-1,2-benzisoxazole |
| US8618157B2 (en) * | 2008-06-20 | 2013-12-31 | Alphapharm Pty. Ltd. | Pharmaceutical formulation |
| NZ590682A (en) | 2008-06-23 | 2012-09-28 | Janssen Pharmaceutica Nv | Crystalline form of (2S)-(-)-N-(6-chloro-2,3-dihydro-benzo[1,4]dioxin-2-ylmethyl)-sulfamide |
| US8592424B2 (en) * | 2008-06-30 | 2013-11-26 | Afgin Pharma Llc | Topical regional neuro-affective therapy |
| US8815939B2 (en) | 2008-07-22 | 2014-08-26 | Janssen Pharmaceutica Nv | Substituted sulfamide derivatives |
| WO2011006012A1 (en) | 2009-07-08 | 2011-01-13 | Charleston Laboratories Inc. | Pharmaceutical compositions |
| US11337962B2 (en) | 2009-09-25 | 2022-05-24 | Upsher-Smith Laboratories, Llc | Formulations comprising triptan compounds |
| DK2480197T3 (en) | 2009-09-25 | 2016-01-25 | Reddys Lab Ltd Dr | Compositions containing triptanforbindelser |
| US10383816B2 (en) | 2015-03-02 | 2019-08-20 | Afgin Pharma, Llc | Topical regional neuro-affective therapy with cannabinoid combination products |
| CA2978605A1 (en) | 2015-03-02 | 2016-09-09 | Afgin Pharma, Llc | Topical regional neuro-affective therapy with cannabinoids |
| ES2842523T3 (es) | 2015-05-15 | 2021-07-14 | Univ Michigan Regents | Métodos y composiciones para el tratamiento de la artritis |
| JP2019507181A (ja) | 2016-03-04 | 2019-03-14 | チャールストン ラボラトリーズ，インコーポレイテッド | 医薬組成物 |
| US20180049994A1 (en) | 2016-08-16 | 2018-02-22 | Afgin Pharma, Llc | Topical regional neuro-affective therapy with caryophyllene |
| US10723718B2 (en) | 2017-11-07 | 2020-07-28 | The Regents Of The University Of Michigan | Small molecule inhibitors of shared epitope-calreticulin interactions and methods of use |
| WO2020049523A1 (en) | 2018-09-07 | 2020-03-12 | Upsher-Smith Laboratories, Llc | Methods of treating migraine |
| US11364225B2 (en) * | 2019-08-21 | 2022-06-21 | Bn Intellectual Properties, Inc. | Pharmaceutical formulation for treating symptoms of migraine and cluster headaches, and method of using the same |
| BR112022016790A2 (pt) * | 2020-02-27 | 2022-11-08 | Biohaven Pharm Holding Co Ltd | Forma de dosagem oral de dispersão rápida de rimegepant |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2162522B (en) * | 1984-08-01 | 1988-02-24 | Glaxo Group Ltd | An indole derivative |
| GB8615599D0 (en) * | 1986-06-26 | 1986-07-30 | Glaxo Group Ltd | Chemical compounds |
| GB8928208D0 (en) * | 1989-12-13 | 1990-02-14 | Glaxo Group Ltd | Medicaments |
-
1990
- 1990-12-12 GB GB909026998A patent/GB9026998D0/en active Pending
-
1991
- 1991-12-10 CZ CS931140A patent/CZ281931B6/cs not_active IP Right Cessation
- 1991-12-10 WO PCT/EP1991/002362 patent/WO1992010477A1/en not_active Ceased
- 1991-12-10 CA CA002098302A patent/CA2098302C/en not_active Expired - Lifetime
- 1991-12-10 YU YU191491A patent/YU48926B/sh unknown
- 1991-12-10 RU RU93053493A patent/RU2108328C1/ru not_active IP Right Cessation
- 1991-12-10 JP JP4501645A patent/JP2994037B2/ja not_active Expired - Lifetime
- 1991-12-10 KR KR1019930701760A patent/KR100211479B1/ko not_active Expired - Fee Related
- 1991-12-10 AU AU90720/91A patent/AU650706B2/en not_active Expired
- 1991-12-11 MX MX9102501A patent/MX9102501A/es unknown
- 1991-12-11 NZ NZ240942A patent/NZ240942A/en not_active IP Right Cessation
- 1991-12-11 IS IS3790A patent/IS1706B/is unknown
- 1991-12-11 EG EG75391A patent/EG20219A/xx active
- 1991-12-11 PT PT99757A patent/PT99757B/pt not_active IP Right Cessation
- 1991-12-11 MY MYPI91002297A patent/MY109265A/en unknown
- 1991-12-11 TW TW080109719A patent/TW205035B/zh not_active IP Right Cessation
- 1991-12-11 TW TW081105493A patent/TW300886B/zh active
- 1991-12-11 BE BE9101129A patent/BE1005085A3/fr not_active IP Right Cessation
- 1991-12-11 FR FR919115359A patent/FR2670487B1/fr not_active Expired - Lifetime
- 1991-12-11 IT ITRM910922A patent/IT1252868B/it active IP Right Grant
- 1991-12-11 NL NL9102071A patent/NL9102071A/nl not_active Application Discontinuation
- 1991-12-11 CH CH3647/91A patent/CH684192A5/fr not_active IP Right Cessation
- 1991-12-11 IE IE431791A patent/IE62894B1/en not_active IP Right Cessation
- 1991-12-11 AP APAP/P/1991/000339A patent/AP230A/en active
- 1991-12-11 CN CN91107596A patent/CN1030890C/zh not_active Expired - Fee Related
- 1991-12-11 ZA ZA919750A patent/ZA919750B/xx unknown
- 1991-12-11 GB GB9126297A patent/GB2251614B/en not_active Revoked
- 1991-12-11 IL IL10033091A patent/IL100330A/en not_active IP Right Cessation
- 1991-12-12 DE DE69108200T patent/DE69108200T2/de not_active Expired - Lifetime
- 1991-12-12 DK DK91311583.8T patent/DK0490689T3/da active
- 1991-12-12 AT AT91311583T patent/ATE119881T1/de not_active IP Right Cessation
- 1991-12-12 EP EP91311583A patent/EP0490689B1/en not_active Expired - Lifetime
- 1991-12-12 ES ES91311583T patent/ES2069836T3/es not_active Expired - Lifetime
-
1995
- 1995-02-20 CN CN95100529A patent/CN1050831C/zh not_active Expired - Fee Related
- 1995-03-16 GR GR940403944T patent/GR3015430T3/el unknown
- 1995-06-02 US US08/460,791 patent/US5554639A/en not_active Expired - Lifetime
- 1995-06-23 HU HU95P/P00422P patent/HU211937A9/hu unknown
-
1996
- 1996-05-21 US US08/651,961 patent/US5705520A/en not_active Expired - Lifetime
-
1997
- 1997-06-19 HK HK82697A patent/HK82697A/en not_active IP Right Cessation
- 1997-12-05 CY CY200597A patent/CY2005A/xx unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TW205035B (OSRAM) | ||
| ES2538359T3 (es) | Métodos para administrar un 1,2,4-oxadiazol activo por vía oral para terapia de supresión de mutación sin sentido | |
| ES2626134T3 (es) | Composiciones de bepotastina | |
| ES2285765T3 (es) | Prevencion antimicrobiana y tratamiento del virus de la inmunodeficiencia humana y de otras enfermedades infecciosas. | |
| TW492876B (en) | New dosage forms of cyclosporine for oral application with single composition and high bioavailability and usual procedure of their manufacture | |
| CN100413494C (zh) | 用于缓解儿科哮喘症状的沙丁胺醇吸入溶液、系统、试剂盒和方法 | |
| JP5695029B2 (ja) | β遮断薬を含む小児用溶液 | |
| TWI834022B (zh) | 化合物及其醫藥用途 | |
| TW200816985A (en) | Methods for buccal, lingual or sublingual dosing regimens of epinephrine for the treatment of allergic emergencies | |
| CN111683683A (zh) | Pde v抑制剂的液体口服制剂 | |
| JP2019031551A (ja) | 女性胃不全麻痺に関係する症状の処置 | |
| US20250064731A1 (en) | A liquid pharmaceutical formulation of clonidine hydrochloride | |
| Pophalkar et al. | Development and evaluation of ondansetron medicated jelly | |
| EP2956131B1 (en) | Treatment of klebsiella pneumoniae with liposomally formulated glutathione | |
| Raja Manali et al. | Oral medicated jelly: a recent advancement in formulation | |
| US10426781B2 (en) | Oral formulation and suspension of an oncology drug | |
| Sarojini et al. | Oral medicated jellies–a review | |
| Darade et al. | Oral medicated jellies as a emerging platform for oral drug delivery in pediatrics | |
| CN102335430A (zh) | 包含咪达唑仑与神经保护剂的复方药物组合物 | |
| CN114007608A (zh) | 在儿科患者中治疗无义突变介导的杜氏肌营养不良症的方法 | |
| TW200934533A (en) | Antimicrobial N-halogenated amino acid salts | |
| CN100387235C (zh) | 松果菊苷的制药新用途 | |
| TW200821296A (en) | Use of sertindole for the preventive treatment of suicidal behaviour | |
| CN101282734A (zh) | 用于局部施用的药物递送系统 | |
| WO2020208398A1 (es) | Composición farmacéutica en polvo con memantina y donepecilo para utilizar en el tratamiento de la enfermedad de alzheimer |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MK4A | Expiration of patent term of an invention patent |